Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Down 13.2% in January

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 576,400 shares, a decrease of 13.2% from the January 15th total of 664,400 shares. Based on an average daily volume of 462,000 shares, the short-interest ratio is presently 1.2 days. Currently, 21.8% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Institutional Trading of Aligos Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Drive Wealth Management LLC bought a new stake in Aligos Therapeutics during the 4th quarter valued at approximately $916,000. Golden State Wealth Management LLC bought a new stake in Aligos Therapeutics during the 4th quarter valued at approximately $107,000. AlphaMark Advisors LLC boosted its stake in Aligos Therapeutics by 1,000.0% during the 4th quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock valued at $44,000 after purchasing an additional 1,000 shares during the period. Northern Trust Corp bought a new stake in Aligos Therapeutics during the 4th quarter valued at approximately $205,000. Finally, Tower Research Capital LLC TRC boosted its stake in Aligos Therapeutics by 2,073.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 652 shares of the company’s stock valued at $26,000 after purchasing an additional 622 shares during the period. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Stock Performance

Shares of NASDAQ ALGS opened at $23.67 on Tuesday. The business’s 50-day simple moving average is $32.79 and its 200-day simple moving average is $20.10. Aligos Therapeutics has a 52 week low of $6.76 and a 52 week high of $46.80. The firm has a market cap of $84.98 million, a price-to-earnings ratio of -1.78 and a beta of 2.45.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).